|
FDA stamps approval on GSK cancer drug Votrient
FierceBiotech GlaxoSmithKline ($GSK) has scored a new US approval for Votrient, making the drug the first new treatment for cancers called soft tissue sarcomas in decades. The FDA nod follows a study that showed that patients on Votrient lived three months longer … |
More: continued here
